FDA Approves Regeneron, Sanofi $37,000 Per Year Eczema Drug

By: Deena Beasley and Bill Berkrot

(Reuters) - The U.S. Food and Drug Administration on Tuesday approved Regeneron Pharmaceuticals Inc and Sanofi SA's Dupixent for treatment of moderate to severe atopic dermatitis, a product widely seen as the most important future growth driver for the two companies.

The drug will have a list price of $37,000 a year, Sanofi said.

Atopic dermatitis is a chronic type of skin inflammation also known as eczema, which in severe cases causes intense constant itching.

Wall Street analysts forecast annual sales exceeding $4 billion by 2022 for the injectable biotech drug known chemically as dupilumab, according to Thomson Reuters data.